Product Description
a Possible PET Ligand for the mGlu2 Receptor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01359852)
Mechanisms of Action: MGLUR2/3 Modulator
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CR017848 | P1 |
Completed |
Schizophrenia |
2011-07-01 |
2019-03-19 |
Treatments |